Merck Stock Trades at $148.74 on Strong Q2 Sales and Pipeline Progress

Key Facts

1Merck reported strong Q2 2026 worldwide sales of $16.6 billion, exceeding consensus estimates.

2The company received FDA approval for WELIREG plus LENVIMA and reported positive results from the BRUNELLO study.

3Guggenheim analysts raised their target price for Merck to $170 with a Buy rating.

Merck reported strong Q2 2026 worldwide sales of $16.6 billion, exceeding consensus estimates of $16.37 billion. According to AD HOC NEWS, the company received FDA approval for the use of WELIREG in combination with LENVIMA and reported positive results from its BRUNELLO study concerning diabetic macular edema.

MRK closed at $148.74 on September 25, 2026, with the stock trading between a day low of $147.48 and a high of $149.94. Following these developments, Guggenheim analysts raised their target price for Merck to $170 with a Buy rating, while the company adjusted its full-year revenue guidance to a range of $66.3 billion to $67.3 billion.